Resverlogix’s 2017 Outlook

Read story

ESC Congress 2017

Read story

ERA-EDTA Congress 2017

Read story

ESC Congress 2016

Read story

EASD 2016

Read story

European Biopharmaceutical Review

Read story

New York Academy of Science Symposium

Read story

The Complement System: Part 1

Read story

The Complement System: Part 2

Read story

The Complement System: Part 3

Read story

Diabetes Mellitus

Read story

Chronic Kidney Disease

Read story

The New Frontier of Epigenetics

Read story

Readers, Writers & Erasers in Epigenetics

Read story

Clinical Trials Series: Part 1

Read story

Clinical Trials Series: Part 2

Read story

Clinical Trials Series: Part 3

Read story

Pharmacoeconomics

Read story

Sanofi Biogenius Competition CTV News feature

Read story

World Diabetes Day

Read story

ESC Congress 2017

On Saturday, August 26, 2017, at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, Resverlogix hosted a satellite symposium titled: "Managing Diabetes & CVD: Is epigenetics a new way forward?"

The agenda and speakers are as follows:

Introduction
Lina Badimon, MD – Barcelona, Spain

Managing high risk diabetes patients with cardiovascular disease: What works, and what else can we do? - Kausik Ray, MD - Imperial College London, United Kingdom

Promise of epigenetic modulation as a target in atherosclerotic patients
- Erik Stroes, MD - Academic Medical Centre, Amsterdam, Netherlands

Insights from the first trials in epigenetics in human: What is the way forward?
- Stephen Nicholls, MD - Adelaide, Australia

Video Presentations & Symposium Highlights can be accessed HERE.